Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature

Clinical and Experimental Rheumatology

Volumn 27, Issue 6, 2009, Pages 1009-1016

  Fernández, Raquel Rios ^a   Rubio, Jose Luis Callejas ^a   Cano, Daniel Sánchez ^a   Moreno, Jose Antonio Sáez ^a   Centeno, Norberto Ortego ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Dermatomyositis; Muscular disease; Myositis; Polymyositis; Rituximab

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CD19 ANTIBODY; CREATINE KINASE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; MEPACRINE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; TAMOXIFEN;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ANAMNESIS; ANTISYNTHETASE SYNDROME; ARTHRITIS; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CARDIOMYOPATHY; CASE REPORT; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DERMATOMYOSITIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROMYOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INTERSTITIAL LUNG DISEASE; INTRADUCTAL CARCINOMA; LABORATORY DIAGNOSIS; LABORATORY TEST; LUNG FUNCTION TEST; MALE; MASTECTOMY; MEDICAL RECORD REVIEW; MEDLINE; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POLYMYOSITIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; RELAPSE; RESPIRATORY TRACT INFECTION; REVIEW; SKIN BIOPSY; SKIN DEFECT; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOSITIS; TREATMENT OUTCOME;

EID: 76649111715     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. PIPITONE N, SALVARANI C: Established and new treatments of the idiopathic inflammatory myopathies: dermatomyositis and polymyositis. Clin Exp Rheumatol 2007; 25: 896-906.
2. COOPER MA, WILLINGHAM DL, BROWN DE, FRENCH AR, SHIH FF, WHITE AJ: Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007; 56: 3107-11.
3. CHIAPPETTA N, STEIER J, GRUBER B: Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005; 11:264-6.
4. BOHAN A, PETER JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
5. RIDER LG, GIANNINI EH, BRUNNER HI et al.: International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50: 2281-90.
6. GOTTENBERG JE, GUILLEVIN L, LAMBOTTE O et al.: Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-20.
7. TOUMA Z, ARAYSSI T, KIBBI L, MASRI AF: Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2008; 75: 334-7.
8. TOKUNAGA M, FUJII K, SAITO K et al.: Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 2005; 44: 176-82.
9. DINH HV, MCCORMACK C, HALL S, PRINCE HM: Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007; 56: 148-53.
10. LEVINE TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52: 601-7.
11. CHUNG L, GENOVESE MC, FIORENTINO DF: A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007; 143: 763-7.
12. HARRISON BA, HECK SI, HOOD AF: A fatal case of dermatomyositis with underlying metastatic esophageal adenocarcinoma. Cutis 2008; 81: 26-8.
13. KAMEDA H, TAKEUCHI T: Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis. Endocr Metab Immune Disord Drug Targets 2006; 6: 409-15.
14. SULTAN SM, NG KP, EDWARDS JC, ISENBERG DA, CAMBRIDGE G: Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008; 26: 887-93.
15. BRULHART L, WALDBURGER JM, GABAY C: Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006; 65: 974-5.
16. KIM KM, KIM HC, JEON KN et al.: Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J 2008; 49: 155-8.
17. WAGNER SA, MEHTA AC, LABER DA: Rituximab-induced interstitial lung disease. Am J Hematol 2007; 82: 916-9.
18. LAMBOTTE O, KOTB R, MAIGNE G, BLANC FX, GOUJARD C, DELFRAISSY JF: Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005; 32: 1369-70.
19. MOK CC, HO LY, TO CH: Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007; 34: 1864-8.
20. FEIST E, DORNER T, SORENSEN H, BURMESTER GR: Longlasting remissions after treatment with rituximab for autoimmune myositis. J Rheumatol 2008; 35: 1230-2.
21. NOSS EH, HAUSNER-SYPEK DL, WEINBLATT ME: Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006; 33: 1021-6.
22. ARLET JB, DIMITRI D, PAGNOUX C et al.: Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006; 16: 334-6.
23. LUTT JR, PISCULLI ML, WEINBLATT ME, DEODHAR A, WINTHROP KL: Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol 2008; 35: 1683-5.